Use of a screening authorization and randomization center for severe sepsis patient qualification and real-time enrollment in a phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist

Detalles Bibliográficos
Autores principales: Schentag, J, Opal, S, Lynn, M, Wittek, A, Wheeler, J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2776178/
http://dx.doi.org/10.1186/cc8061
_version_ 1782174062726873088
author Schentag, J
Opal, S
Lynn, M
Wittek, A
Wheeler, J
author_facet Schentag, J
Opal, S
Lynn, M
Wittek, A
Wheeler, J
author_sort Schentag, J
collection PubMed
description
format Text
id pubmed-2776178
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27761782009-11-13 Use of a screening authorization and randomization center for severe sepsis patient qualification and real-time enrollment in a phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist Schentag, J Opal, S Lynn, M Wittek, A Wheeler, J Crit Care Poster Presentation BioMed Central 2009 2009-11-11 /pmc/articles/PMC2776178/ http://dx.doi.org/10.1186/cc8061 Text en Copyright © 2009 BioMed Central Ltd.
spellingShingle Poster Presentation
Schentag, J
Opal, S
Lynn, M
Wittek, A
Wheeler, J
Use of a screening authorization and randomization center for severe sepsis patient qualification and real-time enrollment in a phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist
title Use of a screening authorization and randomization center for severe sepsis patient qualification and real-time enrollment in a phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist
title_full Use of a screening authorization and randomization center for severe sepsis patient qualification and real-time enrollment in a phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist
title_fullStr Use of a screening authorization and randomization center for severe sepsis patient qualification and real-time enrollment in a phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist
title_full_unstemmed Use of a screening authorization and randomization center for severe sepsis patient qualification and real-time enrollment in a phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist
title_short Use of a screening authorization and randomization center for severe sepsis patient qualification and real-time enrollment in a phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist
title_sort use of a screening authorization and randomization center for severe sepsis patient qualification and real-time enrollment in a phase 2 trial of eritoran tetrasodium (e5564), a tlr4 antagonist
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2776178/
http://dx.doi.org/10.1186/cc8061
work_keys_str_mv AT schentagj useofascreeningauthorizationandrandomizationcenterforseveresepsispatientqualificationandrealtimeenrollmentinaphase2trialoferitorantetrasodiume5564atlr4antagonist
AT opals useofascreeningauthorizationandrandomizationcenterforseveresepsispatientqualificationandrealtimeenrollmentinaphase2trialoferitorantetrasodiume5564atlr4antagonist
AT lynnm useofascreeningauthorizationandrandomizationcenterforseveresepsispatientqualificationandrealtimeenrollmentinaphase2trialoferitorantetrasodiume5564atlr4antagonist
AT witteka useofascreeningauthorizationandrandomizationcenterforseveresepsispatientqualificationandrealtimeenrollmentinaphase2trialoferitorantetrasodiume5564atlr4antagonist
AT wheelerj useofascreeningauthorizationandrandomizationcenterforseveresepsispatientqualificationandrealtimeenrollmentinaphase2trialoferitorantetrasodiume5564atlr4antagonist

Ejemplares similares